We now know where Bayer’s discovery chief, Andreas Busch, is headed.
Shire’s Flemming Ornskov has recruited Busch as his new R&D chief and chief scientific officer, handing him the reins for the pipeline as the CEO completes a mission to remake Shire into a rare disease specialist. And the upwardly mobile Busch will now join the worldwide migration of talent and money into the Cambridge, MA hub where Shire has been planning a big move.
Bayer said yesterday that it had decided to merge the offices for discovery and development chief into one role held by Joerg Moeller after learning that Busch was taking another job. The booming global biopharma sector has become hungry for talent in research and development.
Ornskov temporarily added the R&D chief’s hat to his corporate wardrobe after Phil Vickers exited following a 7-year stint. Vickers recently landed as a biotech CEO, running a Versant-backed startup in Toronto called Northern Biologics.
Busch will arrive at Shire after the company completes a major shakeup in the pipeline, which involves a big move into the thriving Cambridge, MA hub. Last summer the company said it had begun the process of looking for a buyer for its ADHD franchise as Ornskov made it clear that he wanted Shire to complete a transformation into a rare disease company after its big Baxalta buyout.
“Andy is an outstanding scientist with extensive experience leading research and development functions, and an established track record of building broad portfolios that encompass both biologics and small molecules,” said Ornskov in a statement.
The best place to read Endpoints News? In your inbox.
Comprehensive daily news report for those who discover, develop, and market drugs. Join 33,400+ biopharma pros who read Endpoints News by email every day.Free Subscription